Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

PSEHB/PED Notification No.0415-1
PSEHB/MDED Notification No. 0415-1
PSEHB/PSD Notification No. 0415-2
April 15, 2020

To: Directors of Prefectural Health Departments (Bureaus)

Director of Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare
(Official seal omitted)

Director of Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare
(Official seal omitted)

Director of Pharmaceutical Safety Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare
(Official seal omitted)

Post-marketing Safety Measures for Drug-eluting Coronary Stents, etc.

Safety measures for drug-eluting coronary stents, etc. have been shown in Post-marketing Safety Measures for Drug-eluting Coronary Stents (Joint PFSB/ELD Notification No. 0327-1, PFSB/MDRMPED/C Notification No. 0327-1, and PFSB/SD Notification No. 0327-3 by the Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau/ Director for Evaluation and Licensing of Medical Devices and Regenerative Medicines, Minister's Secretariat /Director of Safety Division, Pharmaceutical and Food Safety Bureau, dated March 27, 2015) and Post-marketing Safety Measures for Drug-eluting Absorbable

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Coronary Stents (Joint PSEHB/PED Notification No. 1111-1, PSEHB/MDED Notification No. 1111-2, and PSEHB/SD Notification No. 1111-1 by the Directors of Pharmaceutical Evaluation Division, Medical Device Evaluation Division, and Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated November 11, 2016).

A medical device which is under the category of murine antibody-coated coronary stent (Japanese Medical Device Nomenclature), for which a drug is eluted from a stent to inhibit restenosis has been approved. Based on this, the following is a summary of the safety measure-related matters associated with administration, etc. of antiplatelet agents required for marketing of these drug-eluting coronary stents, etc.

Please notify relevant business entities under your jurisdiction so that Marketing Authorization Holders (MAHs) of drug-eluting coronary stents, etc. take the following safety measures in cooperation with MAHs of antiplatelet agents.

With the issuance of this notification, the notifications in the attachment will be abolished.

1. Drug-eluting Coronary Stents, etc.

   Drug-eluting coronary stents, etc. in this notification refer to medical devices corresponding to the following generic names, for which a drug is eluted from a stent to inhibit restenosis of a coronary artery or a drug is eluted from the site of transcatheter coronary balloon dilatation.

   - Coronary stent
   - Bioabsorbable coronary stent
   - Murine antibody-coated coronary stent
   - Catheter for coronary balloon dilatation angioplasty

2. Holding of Workshops, etc. at the Time of Marketing of Drug-eluting Coronary Stents, etc.

   MAHs of drug-eluting coronary stents, etc. shall for their marketing, hold workshops or medical office explanatory meetings (hereinafter referred to as "workshops, etc.") for proper use, which cover the contents of the warnings and contraindications/prohibitions, etc. in the latest package insert. The marketing of the

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

drug-eluting coronary stents, etc. shall be limited only to medical institutions that have participated in the workshops, etc.

3. Maintenance, etc. of Documents and Patient Notebooks, etc. Describing Important Information for Patients by MAHs of Drug-eluting Coronary Stents, etc.

(1) In order to ensure that patients are thoroughly informed of important matters regarding treatment with drug-eluting coronary stents, etc., MAHs of drug-eluting coronary stents, etc. shall maintain documents and patient notebooks, etc. (hereinafter referred to as "patient explanation documents, etc.") describing important information for patients. By using such documents, the information must be provided to medical institutions, to which the products are supplied, so that an explanation is properly given to patients. For the following matters, special consideration should be given when documents are prepared so that they will stand out for people receiving an explanation.

1) Benefits and risks of use of a drug-eluting coronary stent, etc.
2) Use of an antiplatelet agent in combination with treatment with a drug-eluting coronary stent, etc.
3) There is an antiplatelet agent that needs laboratory tests (hereinafter referred to as "blood tests") including a blood cell count after the start of administration.
4) If blood tests have not been performed with an antiplatelet agent requiring blood tests for reasons such as transfer to another hospital, a physician should be informed accordingly.
5) A physician should be notified immediately if a patient has any subjective symptom.

(2) MAHs of drug-eluting coronary stents, etc. should distribute patient explanation documents, etc. to medical institutions where the products are supplied and be careful not to cause a shortage. In addition, a reminder should periodically be sent to medical institutions regarding the following points.

1) An appropriate explanation should be provided using the patient explanation documents, etc.
2) Because some antiplatelet agents require blood tests after the start of

administration, blood tests should be conducted in compliance with package inserts of concomitant antiplatelet agents.

3) Patients should be instructed to pay sufficient attention to the onset of thrombosis caused by drug-eluting coronary stents, etc. or the onset of adverse reactions of antiplatelet agents and to contact medical institutions immediately if these occur.

4. MAHs of Drug-eluting Coronary Stents, etc. and MAHs of Antiplatelet Agents

The following safety measures should be taken through collaboration between MAHs of drug-eluting coronary stents, etc. and MAHs of antiplatelet agents.

(1) If a patient continues to visit/stay at a medical institution where treatment with a drug-eluting coronary stent, etc. is given, the medical institution should be provided with information necessary for the proper use of antiplatelet agents (for example, recommendation for administration of an antiplatelet agent after treatment with a drug-eluting coronary stent, etc., its recommended administration period, and information on an antiplatelet agent that requires blood tests after the start of administration).

(2) When a patient is transferred to another hospital, MAHs of drug-eluting coronary stents, etc. and antiplatelet agents shall request the necessary cooperation from the primary physician of the medical institution where placement of the drug-eluting coronary stent, etc. was performed, so that the following information is properly provided. In addition, a document describing the following contents shall be prepared and distributed to the medical institution where the patient is transferred.

1) The patient is being treated with a drug-eluting coronary stent, etc.
2) There is a recommendation for administration of an antiplatelet agent after placement of a drug-eluting coronary stent, etc., and there is a recommended administration period.
3) There is an antiplatelet agent that requires blood tests after the start of administration.
4) Patients should be instructed to contact their physician immediately if they experience any subjective symptom.

(3) Information on the proper use of drug-eluting coronary stents, etc. and antiplatelet agents should be collected, and efforts should be made to provide appropriate information to medical institutions where the products are supplied. MAHs of drug-eluting coronary stents, etc. and antiplatelet agents should make efforts to share information when information on defects/adverse reactions related to the drug-eluting coronary stents, etc. and antiplatelet agents is obtained, and safety assurance operations must be performed properly and smoothly.

5. Others

For implementation of safety measures through collaboration between MAHs of drug-eluting coronary stents, etc. and MAHs of antiplatelet agents:

(1) When obtaining new approval for a drug-eluting coronary stent, etc., the MAH of the medical device should promptly notify the Federation of Pharmaceutical Manufacturers' Associations of Japan accordingly.

(2) When obtaining new approval for an antiplatelet agent, the MAH of the drug should promptly notify the Medical Technology Association of Japan (MTJAPAN) accordingly.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Attachment

Partial Revision of 'Post-marketing Safety Measures for Drug-eluting Coronary Stents' (Joint PSEHB/PED Notification No. 0615-1, PSEHB/MDED Notification No. 0615-1, and PSEHB/SD Notification No. 0615-1 by the Directors of Pharmaceutical Evaluation Division/Medical Device Evaluation Division/Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 15, 2017)

Partial Revision of 'Post-marketing Safety Measures for Drug-eluting Coronary Stents' (Joint PSEHB/PED Notification No. 0615-2, PSEHB/MDED Notification No. 0615-2, and PSEHB/SD Notification No. 0615-2 by the Directors of Pharmaceutical Evaluation Division/Medical Device Evaluation Division/Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 15, 2017)

Partial Revision of 'Post-marketing Safety Measures for Drug-eluting Coronary Stents' (Joint PSEHB/PED Notification No. 0615-3, PSEHB/MDED Notification No. 0615-3, and PSEHB/SD Notification No. 0615-3 by the Directors of Pharmaceutical Evaluation Division/Medical Device Evaluation Division/Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 15, 2017)

Post-marketing Safety Measures Related to Drug-eluting Absorbable Coronary Stents (Joint PSEHB/PED Notification No. 1111-1, PSEHB/MDED Notification No. 1111-2, and PSEHB/SD Notification No. 1111-1 by the Directors of Pharmaceutical Evaluation Division/Medical Device Evaluation Division/Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated November 11, 2016)

Post-marketing Safety Measures Related to Drug-eluting Absorbable Coronary Stents (Joint PSEHB/PED Notification No. 1111-2, PSEHB/MDED Notification No. 1111-3, and PSEHB/SD Notification No. 1111-2 by the Directors of Pharmaceutical Evaluation Division/Medical Device Evaluation Division/Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated November 11, 2016)

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Post-marketing Safety Measures Related to Drug-eluting Absorbable Coronary Stents (Joint PSEHB/PED Notification No. 1111-3, PSEHB/MDED Notification No. 1111-4, and PSEHB/SD Notification No. 1111-3 by the Directors of Pharmaceutical Evaluation Division/Medical Device Evaluation Division/Safety Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated November 11, 2016)

Post-marketing Safety Measures for Drug-eluting Coronary Stents (Joint PFSB/ELD Notification No. 0327-1, PFSB/MDRMPED Notification No. 0327-1, and PFSB/SD Notification No. 0327-3 by the Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW/Counsellor, Minister's Secretariat [Medical Device and Regenerative Medicine Product Evaluation Division]/Director of Safety Division, Pharmaceutical and Food Safety Bureau, dated March 27, 2015)

Post-marketing Safety Measures for Drug-eluting Coronary Stents (Joint PFSB/ELD Notification No. 0327-2, PFSB/MDRMPED Notification No. 0327-2, and PFSB/SD Notification No. 0327-4 by the Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau/Counsellor, Minister's Secretariat [Medical Device and Regenerative Medicine Product Evaluation Division]/Director of Safety Division, Pharmaceutical and Food Safety Bureau, dated March 27, 2015)

Post-marketing Safety Measures for Drug-eluting Coronary Stents (Joint PFSB/ELD Notification No. 0327-3, PFSB/MDRMPED Notification No. 0327-3, and PFSB/SD Notification No. 0327-5 by the Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW/Counsellor, Minister's Secretariat [Medical Device and Regenerative Medicine Product Evaluation Division]/Director of Safety Division, Pharmaceutical and Food Safety Bureau, dated March 27, 2015)

Proper Use of Antiplatelet Agents and XIENCE Alpine Drug-eluting Stents (Joint PFSB/MDRMPED Notification No. 1222-2 and PFSB/SD Notification No. 1222-2 by the Counsellor, Minister's Secretariat, MHLW [Medical Device and Regenerative Medicine Product Evaluation Division]/Director of Safety Division, Pharmaceutical and Food Safety Bureau, dated December 22, 2014)

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Proper Use of Antiplatelet Agents and PROMUS Premier LV Stent Systems (Joint PFSB/MDRMPED Notification No. 1128-1 and PFSB/SD Notification No. 1128-12 by the Counsellor, Minister's Secretariat, MHLW [Medical Device and Regenerative Medicine Product Evaluation Division]/Director of Safety Division, Pharmaceutical and Food Safety Bureau, dated November 28, 2014)

Proper Use of Antiplatelet Agents and PROMUS Premier Stent Systems (Joint PFSB/ELD Notification No. 0509-1 and PFSB/SD Notification No. 0509-1 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated May 9, 2014)

Proper Use of Antiplatelet Agents and SeQuent Please Drug-eluting Balloon Catheters (Joint PFSB/ELD Notification No. 0827-3 and PFSB/SD Notification No. 0827-3 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated August 27, 2013)

Proper Use of Antiplatelet Agents and SeQuent Please Drug-eluting Balloon Catheters (Joint PFSB/ELD Notification No. 0827-4 and PFSB/SD Notification No. 0827-4 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated August 27, 2013)

Proper Use of Antiplatelet Agents and SeQuent Please Drug-eluting Balloon Catheters (Joint PFSB/ELD Notification No. 0827-6 and PFSB/SD Notification No. 0827-6 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated August 27, 2013)

Proper Use of Antiplatelet Agents and Resolute Integrity SV Coronary Stent Systems (PFSB/ELD Notification No. 0827-2 and PFSB/SD Notification No. 0827-2 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated August 27, 2013)

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Proper Use of Antiplatelet Agents, XIENCE PRIME SV Drug-eluting Stents, and XIENCE Xpedition Drug-eluting Stents (Joint PFSB/ELD Notification No. 0827-1 and PFSB/SD Notification No. 0827-1 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated August 27, 2013)

Proper Use of Antiplatelet Agents and PROMUS Element Plus Stent Systems (Joint PFSB/ELD Notification No. 0906-13 and PFSB/SD Notification No. 0906-4 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated September 6, 2012)

Proper Use of Antiplatelet Agents and Resolute Integrity Coronary Stent Systems (Joint PFSB/ELD Notification No. 0518-1 and PFSB/SD Notification No. 0518-1 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated May 18, 2012)

Proper Use of Antiplatelet Agents and XIENCE PRIME Drug-eluting Stents (Joint PFSB/ELD Notification No. 0406-4 and PFSB/SD Notification No. 0406-1 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated April 6, 2012)

Proper Use of Antiplatelet Agents and PROMUS Element Stent Systems (Joint PFSB/ELD Notification No. 0208-1 and PFSB/SD Notification No. 0208-4 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW)

Proper Use of Antiplatelet Agents and TAXUS Element Stent Systems (Joint PFSB/ELD Notification No. 0905-2 and PFSB/SD Notification No. 0905-1 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated September 5, 2011)

Request for Cooperation for Safety Measures for Antiplatelet Agents and NOBORI (Joint PFSB/ELD/OMDE Notification No. 0720-2 and PFSB/SD Notification No. 0720-2 by the

Directors of Office of Medical Devices Evaluation, Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated July 20, 2011)

Request for Cooperation for Safety Measures for Antiplatelet Agents and NOBORI (Joint PFSB/ELD Notification No. 0309-4 and PFSB/SD Notification No. 0309-4 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 9, 2011)

Proper Use of Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0309-3 and PFSB/SD Notification No. 0309-3 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 9, 2011)

Proper Use of Clopidogrel Sulfate Preparations and Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0309-2 and PFSB/SD Notification No. 0309-2 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 9, 2011)

Proper Use of NOBORI (Joint PFSB/ELD Notification No. 0309-1 and PFSB/SD Notification No. 0309-1 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 9, 2011)

Request for Cooperation for Safety Measures for Antiplatelet Agents, XIENCE V Drug-eluting Stents, and PROMUS Drug-eluting Stents (Joint PFSB/ELD Notification No. 0112-8 and PFSB/SD Notification No. 0112-10 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January 12, 2010)

Proper Use of Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0112-6 and PFSB/SD Notification No. 0112-8 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

12, 2010)

Proper Use of Clopidogrel Sulfate Preparations and Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0112-5 and PFSB/SD Notification No. 0112-7 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January 12, 2010)

Proper Use of XIENCE V Drug-eluting Stents and PROMUS Drug-eluting Stents (Joint PFSB/ELD Notification No. 0112-4 and PFSB/SD Notification No. 0112-6 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January 12, 2010)

Proper Use of Endeavor Sprint Coronary Stent Systems (Joint PFSB/ELD Notification No. 0112-3 and PFSB/SD Notification No. 0112-5 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January 12, 2010)

Proper Use of Cypher Select+ Stents (Joint PFSB/ELD Notification No. 0112-2 and PFSB/SD Notification No. 0112-4 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January 12, 2010)

Request for Cooperation for Safety Measures for Antiplatelet Agents and Endeavor Coronary Stent Systems (Joint PFSB/ELD Notification No. 0324005 and PFSB/SD Notification No. 0324010 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 24, 2009)

Proper Use of Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0324003 and PFSB/SD Notification No. 0324008 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 24, 2009)

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Proper Use of Clopidogrel Sulfate Preparations and Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0324002 and PFSB/SD Notification No. 0324007 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 24, 2009)

Proper Use of Endeavor Coronary Stent Systems (Joint PFSB/ELD Notification No. 0324001 and PFSB/SD Notification No. 0324006 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated March 24, 2009)

Proper Use of TAXUS Liberte Stent Systems (Joint PFSB/ELD Notification No. 0128001 and PFSB/SD Notification No. 0128001 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated January 28, 2009)

Request for Cooperation for Safety Measures for Ticlopidine Hydrochloride Preparations and TAXUS Express 2 Stents (Joint PFSB/ELD Notification No. 0420006 and PFSB/SD Notification No. 0420004 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated April 20, 2007)

Proper Use of Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0420004 and PFSB/SD Notification No. 0420002 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated April 20, 2007)

Proper Use of Ticlopidine Hydrochloride Preparations (Joint PFSB/ELD Notification No. 0730002 and PFSB/SD Notification No. 0730002 by the Directors of Evaluation and Licensing Division/Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, dated July 30, 2004)

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp